Table 1.
Characteristic | Value |
---|---|
Patient age in years, mean (SD) | 60.6 (11) |
TiOS score, mean (SD) | 4.1 (0.6) |
Consultation duration, mean (SD), min | 00:28:03 (00:12:29) |
OPTION-12 sum score, mean (SD) | 15.5 (11.6) |
Education, n (%) | |
High | 29 (29) |
Intermediate | 51 (50) |
Low | 21 (21) |
Marital status, n (%) | |
Single | 35 (35) |
In a relationship | 66 (65) |
Has children, n (%) | 84 (83) |
Preferred level of involvement in decision making, n (%) | |
Patient driven | 39 (39) |
Shared | 41 (41) |
Oncologist driven | 21 (21) |
Consultations with university hospital oncologists, n (%) | 20 (20) |
Consultations with use of Adjuvant! online, n (%) | 60 (59) |
Tumor size, n (%) | |
0–20 mm | 58 (58) |
≥21 mm | 42 (42) |
Missing | 1 |
Tumor stage,an (%) | |
Stage I | 43 (43) |
Stages II and III | 58 (57) |
Tumor positive lymph nodes present, n (%) | 33 (33) |
Positive estrogen receptor (ER) status (n = 96), n (%) | 84 (88) |
Missing | 5 |
Positive progesterone receptor (PR) status (n = 95), n (%) | 73 (77) |
Missing | 6 |
Positive HER2/neu receptor status, n (%) | 7 (7) |
Missing | 5 |
Triple negative (i.e., ER/PR/HER2/neu negative; n = 96), n (%) | 10 (10) |
Missing | 5 |
Surgery (n = 96), n (%) | |
Breast conserving | 51 (53) |
Mastectomy | 45 (47) |
Missing | 5 |
Has received radiotherapy (n = 96), n (%) | 54 (56) |
Missing | 5 |
Treatment(s) discussed during the consultation, n (%) | |
Chemotherapy only | 12 (12) |
Endocrine therapy only | 18 (18) |
Chemotherapy and endocrine therapy | 70 (70) |
Chemotherapy decision (yes; n = 94), n (%) | 53 (57) |
Missing | 7 |
Endocrine therapy decision (yes; n = 93), n (%) | 79 (85) |
Missing | 8 |
OPTION-12, 12-item Observing Patient Involvement In Decision Making scale; TiOS, Trust in Oncologist Scale.
TNM staging source: American Joint Committee on Cancer. Cancer Staging Manual. 7th ed. Chicago, IL: American College of Surgeons, 2015.